Falcon Point Capital’s Heron Therapeutics HRTX Stock Holding History

Falcon Point Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-33,379	Closed	-$501K	–	118
2017 Q1	$501K	Buy	+33,379	New	+$462K	0.07%	100
2016 Q1	–	Sell	-10,897	Closed	-$291K	–	125
2015 Q4	$291K	Buy	+10,897	New	+$291K	0.06%	102

Other funds holding HRTX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Falcon Point Capital's HRTX Position: Q2 2017 in Review

Falcon Point Capital sold out of Heron Therapeutics (HRTX) in Q2 2017, closing a stake of 33,379 shares — an estimated $501K sold.

Falcon Point Capital first reported a position in HRTX in Q4 2015 and held it in 2 quarters. The position peaked at $501K in Q1 2017. 104 funds tracked by Wall St. Rank hold HRTX as of Q2 2017.

Falcon Point Capital reported no remaining Heron Therapeutics position as of Q2 2017 after selling out during the quarter.
Falcon Point Capital sold 33,379 Heron Therapeutics shares in Q2 2017, an estimated $501K.
Falcon Point Capital first reported a position in Heron Therapeutics in Q4 2015 and held it in 2 quarters.
Falcon Point Capital's Heron Therapeutics position peaked at $501K in Q1 2017.
104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2017.

Based on Falcon Point Capital's 13F filing for Q2 2017, filed 2 Aug 2017.